Elicio Therapeutics Inc
(ELTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -51,232 | -33,563 | -13,222 | -40,658 |
| Depreciation Amortization | 3,222 | 894 | 328 | 496 |
| Accounts receivable | -86 | 156 | -140 | N/A |
| Accounts payable and accrued liabilities | -6,530 | 5,815 | 1,445 | N/A |
| Other Working Capital | -7,670 | 6,141 | 2,611 | 9,750 |
| Other Operating Activity | 18,817 | -980 | 245 | 5,823 |
| Operating Cash Flow | $-43,479 | $-21,537 | $-8,733 | $-24,589 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -31 | -30 | -20 | -242 |
| Investing Cash Flow | $-31 | $-30 | $-20 | $-242 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 32,118 | 14,833 | 3,051 | N/A |
| Common Stock Issued | 42 | 4 | 0 | N/A |
| Other Financing Activity | 20,047 | 6,153 | 885 | 4,890 |
| Financing Cash Flow | $52,207 | $20,990 | $3,936 | $4,890 |
| Exchange Rate Effect | -157 | 47 | 233 | 0 |
| Beginning Cash Position | 5,571 | 5,571 | 5,571 | 25,512 |
| End Cash Position | 14,111 | 5,041 | 987 | 5,571 |
| Net Cash Flow | $8,540 | $-530 | $-4,584 | $-19,941 |
| Free Cash Flow | ||||
| Operating Cash Flow | -43,479 | -21,537 | -8,733 | -24,589 |
| Capital Expenditure | -31 | -30 | -20 | N/A |
| Free Cash Flow | -43,510 | -21,567 | -8,753 | -24,589 |